Milestone Pharmaceuticals is trading at $0.89 (+8.80%) in pre-market; no clear company-specific catalyst for the move surfaced. - The latest identified company announcement was September 24, reporting enrollment of the first Canadian participant in its Phase 3 AFib-RVR trial. It predates the move and does not establish its cause. - The supplied market snapshot shows modestly higher indexes, but no clear broad-market explanation for the sharp gain.